What is Nektar Therapeutics's G&A?

Nektar Therapeutics (NKTR) reported G&A of $13.44M in Q1 2026.

How has Nektar Therapeutics's G&A changed year-over-year?

Nektar Therapeutics's G&A decreased by 44.8% year-over-year, from $24.35M to $13.44M.

What is the long-term trend for Nektar Therapeutics's G&A?

Over 4 years (2021 to 2025), Nektar Therapeutics's G&A has grown at a -13.5% compound annual growth rate (CAGR), from $122.84M to $68.67M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Nektar Therapeutics NKTR G&A

G&A at other companies

Apogee Therapeutics, Inc.APGE

$21.95M+31.4%

ImmunomeIMNM

$12.95M+21.1%

Vera TherapeuticsVERA

$39.12M+146%

Iovance Biotherapeutics, Inc.IOVA

$38.95M-11.1%

Kymera TherapeuticsKYMR

$20.36M+25.1%

Arcus BiosciencesRCUS

$29M+3.6%

Other financials

Income statement

See full

Revenue$10.9M+3.8%

Gross profit$21.8M+2.9%

Operating income-$39.1M+12.3%

Net income-$44.9M+11.7%

EPS (diluted)-$1.82+49.7%

Balance sheet

See full

Cash & equivalents$5.7M-20.0%

Total debt$83.2M-17.1%

Total equity$576.2M+4,094%

Total assets$763.3M+198%

Cash flow

See full

Operating cash flow-$44.3M+9.7%

CapEx$18.0K+800%

Free cash flow-$44.3M+9.7%

Valuation

See full

Market cap$2.25B+1,531%

Enterprise value$2.33B+874%

P/S40.5×+38.9×

Profitability

See full

Gross margin100%+31.2pp

Operating margin-242%—

Net margin-284.2%+937pp

FCF margin-366.6%+1,421pp

Returns & leverage

See full

Return on equity-53.6%-22.6pp

Debt / equity0.1×-7.2×

Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nektar Therapeutics's G&A?: Nektar Therapeutics (NKTR) reported G&A of $13.44M in Q1 2026.
How has Nektar Therapeutics's G&A changed year-over-year?: Nektar Therapeutics's G&A decreased by 44.8% year-over-year, from $24.35M to $13.44M.
What is the long-term trend for Nektar Therapeutics's G&A?: Over 4 years (2021 to 2025), Nektar Therapeutics's G&A has grown at a -13.5% compound annual growth rate (CAGR), from $122.84M to $68.67M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.